Notes · Pharmacology · 7 November 2026

Beta blockers: classification, mechanism, indications & adverse effects

Definition

• Beta‑adrenergic blockers (β‑blockers) are a class of drugs that competitively inhibit the action of catecholamines (epinephrine and norepinephrine) at β‑adrenergic receptors, thereby reducing sympathetic stimulation of the heart, vasculature, and other organs.

Classification

• Based on receptor selectivity
  • Non‑selective β‑blockers block both β1 and β2 receptors (e.g., propranolol, nadolol, timolol).
  • Cardio‑selective (β1‑selective) blockers preferentially block β1 receptors (e.g., metoprolol, atenolol, bisoprolol, nebivolol).
• Based on intrinsic sympathomimetic activity (ISA) – some β‑blockers partially activate β receptors while blocking them (e.g., pindolol, acebutolol).
• Based on additional pharmacologic actions
  • α‑blocking β‑blockers (e.g., carvedilol, labetalol) also antagonize α1 receptors, causing vasodilation.
  • Vasodilatory β‑blockers (e.g., nebivolol) release nitric oxide, producing arterial dilation.
• Based on duration of action
  • Short‑acting (e.g., propranolol, atenolol) require multiple daily doses.
  • Long‑acting (once‑daily) (e.g., bisoprolol, carvedilol) have a half‑life ≥12 h.

Mechanism of Action

• Receptor antagonism – β‑blockers bind to the intracellular domain of β‑adrenergic receptors, preventing catecholamine‑induced activation of adenylate cyclase.
• ↓ cyclic AMP (cAMP) – reduced cAMP leads to decreased protein kinase A activity, which in turn lowers calcium influx into cardiac myocytes.
• Cardiac effects – ↓ heart rate (negative chronotropy), ↓ myocardial contractility (negative inotropy), and ↓ conduction velocity through the atrioventricular node (negative dromotropy).
• Renin‑angiotensin system inhibition – β1 blockade in juxtaglomerular cells reduces renin release, attenuating downstream angiotensin II‑mediated vasoconstriction.
• Additional actions – α‑blocking agents antagonize vasoconstriction; vasodilatory agents increase nitric oxide synthesis, improving endothelial function.

Pharmacokinetics (Key Points)

• Absorption – most β‑blockers are well absorbed orally; bioavailability varies (e.g., propranolol ≈25 % due to first‑pass metabolism, atenolol ≈50 %).
• Distribution – lipophilic agents (propranolol, carvedilol) cross the blood‑brain barrier, causing central side effects; hydrophilic agents (atenolol, sotalol) have limited CNS penetration.
• Metabolism – hepatic metabolism via cytochrome P450 (especially CYP2D6) for lipophilic drugs; renal excretion predominates for hydrophilic drugs.
• Elimination half‑life – short‑acting agents ≈3–6 h; long‑acting agents ≈12–24 h, allowing once‑daily dosing.

Indications (Current Guidelines, 2023‑2024)

• Hypertension – β‑blockers are recommended as part of combination therapy, especially in patients with concomitant coronary artery disease (CAD) or heart failure.
• Ischemic heart disease (stable angina, post‑myocardial infarction) – reduce myocardial oxygen demand by lowering heart rate and contractility; guideline‑directed therapy includes β‑blockers within 24 h of acute MI (Class I, Level A).
• Heart failure with reduced ejection fraction (HFrEF) – carvedilol, bisoprolol, and metoprolol succinate improve survival and reduce hospitalizations (Class I, Level A).
• Arrhythmias – control ventricular rate in atrial fibrillation/flutter; prevent supraventricular tachycardia; class II anti‑arrhythmic effect.
• Migraine prophylaxis – non‑selective agents (propranolol) are first‑line preventive drugs.
• Thyrotoxicosis – β‑blockers (especially propranolol) control peripheral adrenergic symptoms and inhibit peripheral conversion of T4 to T3.
• Glaucoma – topical β‑blockers (timolol) lower intra‑ocular pressure by decreasing aqueous humor production.

Contraindications & Cautions

• Absolute contraindications – severe bradycardia (<50 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, decompensated heart failure, severe bronchial asthma, and overt peripheral vascular disease (for non‑selective agents).
• Relative contraindications – diabetes mellitus (masking hypoglycaemia), chronic obstructive pulmonary disease (use cardio‑selective agents), Raynaud’s phenomenon, and severe depression.

Adverse Effects (Common & Clinically Important)

• Cardiovascular – bradycardia, hypotension, atrioventricular block, and worsening heart failure (especially with abrupt initiation in decompensated patients).
• Respiratory – bronchospasm in asthmatics (more likely with non‑selective agents).
• Metabolic – masking of hypoglycaemic symptoms (tachycardia, tremor) in diabetic patients; may impair glycogenolysis.
• Central nervous system – fatigue, depression, vivid dreams, and, rarely, psychosis (more common with lipophilic agents).
• Peripheral – cold extremities, Raynaud’s phenomenon, and sexual dysfunction (erectile dysfunction).
• Endocrine – hyperglycaemia and dyslipidaemia (especially with non‑selective agents).
• Gastro‑intestinal – nausea, diarrhoea, and abdominal cramps.

Drug Interactions

• Additive negative chronotropic effects – with calcium‑channel blockers (verapamil, diltiazem), digoxin, and other AV‑node blockers; monitor heart rate and ECG.
• Enhanced β‑blockade – with clonidine withdrawal, MAO inhibitors, and certain antidepressants (e.g., fluoxetine).
• Altered metabolism – CYP2D6 inhibitors (e.g., quinidine, fluoxetine) increase plasma levels of metoprolol and carvedilol; dose reduction may be required.
• Potassium‑sparing diuretics – concurrent use with β‑blockers can precipitate hyperkalaemia in renal failure.

Monitoring Parameters

• Baseline – heart rate, blood pressure, ECG (especially PR interval), renal function, and blood glucose (in diabetics).
• Follow‑up – check heart rate and blood pressure within 1–2 weeks of initiation or dose change; repeat ECG if symptomatic bradycardia or AV block is suspected.
• Heart failure patients – monitor left ventricular ejection fraction (echocardiography) and signs of fluid overload after dose titration.

High‑Yield Exam Points

• β1 receptors are predominantly located in the heart; β2 receptors are mainly in bronchial smooth muscle and vasculature.
• Cardio‑selective β‑blockers are preferred in patients with reactive airway disease because they spare β2‑mediated bronchodilation.
• ISA (intrinsic sympathomimetic activity) agents are less likely to cause bradycardia and are useful in patients with peripheral arterial disease.
• Carvedilol has both β‑blocking and α1‑blocking activity; it reduces after‑load and is a cornerstone drug in HFrEF.
• Beta‑blockers can mask hypoglycaemia – they blunt tachycardia and tremor, the classic warning signs of low blood glucose.
• Propranolol is the drug of choice for migraine prophylaxis and for controlling symptoms of thyrotoxicosis.
• Abrupt withdrawal of β‑blockers can precipitate rebound tachycardia, hypertension, and angina; taper gradually.

Practice questions

1. A 58‑year‑old man with a recent anterior myocardial infarction is started on a β‑blocker. Which of the following agents is recommended by the 2023 ACC/AHA guideline for post‑MI therapy?
A. Propranolol
B. Metoprolol succinate
C. Atenolol
D. Pindolol

Answer: B — metoprolol succinate is the guideline‑preferred β‑blocker for post‑MI patients because of its β1 selectivity and once‑daily dosing.

2. Which β‑blocker possesses intrinsic sympathomimetic activity and is therefore least likely to cause worsening peripheral arterial disease?
A. Carvedilol
B. Bisoprolol
C. Pindolol
D. Labetalol

Answer: C — pindolol has ISA, providing mild β‑agonist activity that reduces the risk of peripheral vasoconstriction.

3. A diabetic patient on insulin therapy is started on propranolol for hypertension. Which clinical effect is most concerning?
A. Increased insulin secretion
B. Masking of hypoglycaemic symptoms
C. Enhanced glycogenolysis
D. Lowering of fasting blood glucose

Answer: B — propranolol can mask the tachycardia and tremor that warn of hypoglycaemia, increasing the risk of severe low blood glucose episodes.

More in Pharmacology

AI-assisted study material for exam revision. Always confirm with standard textbooks and current guidelines; not medical advice.